BL-M05D1 / Biokin Pharma - LARVOL DELTA

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: SystImmune Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Biliary Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors (clinicaltrials.gov) - P1 | N=120 | Not yet recruiting | Sponsor: SystImmune Inc.

New P1 trial • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

BL-M05D1-101: A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

BL-M05D1, a novel claudin 18.2-targeting ADC, demonstrates specific potent anti-tumor efficacy in preclinical evaluation (AACR 2024) - "In summary, these studies suggest BL-M05D1, a novel Claudin 18.2-targeting ADC, is potentially efficacious in the treatment of Claudin 18.2-expressing carcinomas. The clinical phase I is being undertaken to evaluate safety, dosing and observations of preliminary signs of efficacy."

Preclinical • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18 • CTSB

A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor